Trevi Therapeutics Inc [NASDAQ: TRVI] traded at a high on 2025-11-27, posting a 16.99 gain after which it closed the day’ session at $13.29.
The results of the trading session contributed to over 5474773 shares changing hands. Over the past one week, the price volatility of Trevi Therapeutics Inc stands at 9.07% while the volatility over the past one month is 6.88%.
The market cap for TRVI stock reached $1.70 billion, with 128.22 million shares outstanding and 83.78 million shares in the current float. Compared to the average trading volume of 2.19M shares, TRVI reached a trading volume of 5474773 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Trevi Therapeutics Inc [TRVI]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TRVI shares is $20.83 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TRVI stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Leerink Partners have made an estimate for Trevi Therapeutics Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on November 13, 2025. While these analysts kept the previous recommendation, Morgan Stanley raised their target price to Overweight. The new note on the price target was released on August 21, 2025, representing the official price target for Trevi Therapeutics Inc stock. Previously, the target price had yet another raise to $25, while Cantor Fitzgerald analysts kept a Overweight rating on TRVI stock.
The Price to Book ratio for the last quarter was 8.98, with the Price to Cash per share for the same quarter was set at 1.52.
How has TRVI stock performed recently?
Trevi Therapeutics Inc [TRVI] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 20.38. With this latest performance, TRVI shares gained by 26.21% in over the last four-week period, additionally plugging by 108.96% over the last 6 months – not to mention a rise of 222.57% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TRVI stock in for the last two-week period is set at 72.00, with the RSI for the last a single of trading hit 0.84, and the three-weeks RSI is set at 0.71 for Trevi Therapeutics Inc [TRVI]. The present Moving Average for the last 50 days of trading for this stock 10.38, while it was recorded at 11.54 for the last single week of trading, and 7.42 for the last 200 days.
Trevi Therapeutics Inc (TRVI) Capital Structure & Debt Analysis
According to recent financial data for Trevi Therapeutics Inc. ( TRVI), the Return on Equity (ROE) stands at -36.87%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -34.19%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Trevi Therapeutics Inc’s Return on Invested Capital (ROIC) is -24.10%, showcasing its effectiveness in deploying capital for earnings.
Trevi Therapeutics Inc (TRVI) Efficiency & Liquidity Metrics
Based on Trevi Therapeutics Inc’s (TRVI) latest financial statements, the Debt-to-Equity Ratio is 0.00%, indicating its reliance on debt financing relative to shareholder equity.
Trevi Therapeutics Inc (TRVI) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Trevi Therapeutics Inc. (TRVI) effectively leverages its workforce, generating an average of -$1763846.15 per employee. The company’s liquidity position is robust, with a Current Ratio of 21.93% and a Quick Ratio of 21.93%, indicating strong ability to cover short-term liabilities.
Earnings analysis for Trevi Therapeutics Inc [TRVI]
With the latest financial reports released by the company, Trevi Therapeutics Inc posted -0.11/share EPS, while the average EPS was predicted by analysts to be reported at -0.12/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.01. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TRVI. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Trevi Therapeutics Inc go to -9.78%.
Insider trade positions for Trevi Therapeutics Inc [TRVI]
There are presently around $102.74%, or 103.44%% of TRVI stock, in the hands of institutional investors. The top three institutional holders of TRVI stocks are: NEA MANAGEMENT COMPANY, LLC with ownership of 11.37 million shares, which is approximately 11.2532%. FRAZIER LIFE SCIENCES MANAGEMENT, L.P., holding 7.38 million shares of the stock with an approximate value of $$22.0 million in TRVI stocks shares; and FRAZIER LIFE SCIENCES MANAGEMENT, L.P., currently with $$14.98 million in TRVI stock with ownership which is approximately 4.9751%.
